INSM

Insmed Incorporated

$95.29

-1.02% 2026-10-19

Healthcare

1M 3M 6M 1Y 2Y

INSMSPY

-3.3%

-20.6%

-11.0%

-33.3%

YTD

-45.2%

-42.5%

Grades vs sector

Momentum

no data

–

Percentile within its GICS sector across the S&P 1500.

Growth

no data

–

Percentile within its GICS sector across the S&P 1500.

Value

no data

–

Percentile within its GICS sector across the S&P 1500.

Profitability

no data

–

Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 3 live models right now.

Momentum Top 15

not ranked (outside this model's universe or screens)

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

Key stats

Market cap$20.8B

P/E (trailing)–

P/E (forward)119.5

52-week range90.39 – 212.75

Revenue growth (YoY, latest qtr)+296.1%

Dividend yield0.00%

Analyst consensusStrong Buy (22)

Mean price target$197.00 (+107%)

Valuation & fundamentals

Bottom line

No cash-flow valuation

Model read-out from the numbers below, not advice. Score +0 (DCF counts double).

▼Piotroski F-score3/9

▲Altman Z5.3 (safe)

▲Analyst target+107% (22 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.

Reverse DCFfor context, not a signal

Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.82 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $0.80 vs trailing $-4.10. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin

11.5%

Operating margin

-73.9%

FCF margin

-71.0%

Net margin

-76.9%

Return on equity

-115.6%

Return on invested capital

-181.9%

Net debt / EBITDA

–

Current ratio

3.7×

Interest cover

-10.3×

Cash conversion (OCF/NI)

–

Piotroski F-score 3/9 · last two fiscal years

✗ Positive net income✗ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 5.3 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$197

+107%

Analysts

Strong Buy

Range

$165–$243

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$606.4M	$-1.3B	$-967.6M
2024	$363.7M	$-913.8M	$-705.8M
2023	$305.2M	$-749.6M	$-549.5M
2022	$245.4M	$-481.5M	$-410.3M
2021	$188.5M	$-434.7M	$-370.6M
2020	$164.4M	$-294.1M	$-225.6M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +35.2%.

Earnings

Next report: 2026-10-29 · before open · EPS est -0.38

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-06	-0.68	-0.06	+91.2%
2026-05-07	-1.00	-0.76	+23.9%
2026-02-19	-1.17	-1.54	-31.9%
2025-10-30	-1.37	-1.75	-27.8%
2025-08-07	-1.31	-1.70	-29.6%
2025-05-08	-1.36	-1.42	-4.2%
2025-02-20	-1.16	-1.32	-13.3%
2024-10-31	-1.25	-1.27	-1.9%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$425.5M	+296.1%
2026-03-31	$306.0M	–
2025-12-31	$263.8M	–
2025-09-30	$142.3M	–
2025-06-30	$107.4M	–

Analyst actions

Wolfe Research

2026-10-12 · down

Outperform → Peer Perform

HC Wainwright & Co.

2026-10-12 · reit

Buy → Buy
PT $220

Barclays

2026-09-30 · main

Overweight → Overweight
PT $207

Roth Capital

2026-09-15 · reit

Buy → Buy
PT $198

JP Morgan

2026-08-10 · main

Overweight → Overweight
PT $175

Truist Securities

2026-08-10 · reit

Buy → Buy
PT $195

Insider trades

Brennan David R

Director · 2026-09-09

SELL
$3.1M

Sharoky Melvin Md

Director · 2026-08-17

SELL
$637.6K

Adsett Roger

Chief Operating Officer · 2026-08-10

SELL
$32.0M

Flammer Martina M.D.

Chief Medical Officer · 2026-08-06

SELL
$1.1M

Flammer Martina M.D.

Chief Medical Officer · 2026-08-06

SELL
$2.4M

Lewis William

Director, Chair and CEO · 2026-07-23

SELL
$509.9K

Lewis William

Director, Chair and CEO · 2026-07-23

SELL
$625.0K

News

Insmed Launches Brinsupri Tablet in Japan for Non-Cystic Fibrosis Bronchiectasis

MT Newswires · 15h ago

Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

PR Newswire · 16h ago

Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

PR Newswire · Oct 15

Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026

PR Newswire · Oct 14

Insmed Shares Fall After Wolfe Research Downgrade

MT Newswires · Oct 12

Wolfe Research Downgrades Insmed to Peer Perform From Outperform

MT Newswires · Oct 12

Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative?

Simply Wall St. · Oct 08

Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

BioPharma Dive · Oct 07

INSM Stock Slides on CFO Exit, Reiterates '26 Sales View

Zacks · Oct 06

Insmed stock falls as CFO Sara Bonstein to step down

Investing.com · Oct 05

Stats refreshed 2026-10-19 19:02:15 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Hypothetical research for education, not investment advice. Data: Yahoo Finance (via yfinance, delayed), SEC EDGAR.

Disclaimer Terms Privacy Glossary Track record Data status